Document Detail


[Bowel perforation associated with bevacizumab therapy in recurrent ovarian cancers without bowel obstruction or bowel involvement].
MedLine Citation:
PMID:  19011357     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Recent reports showed that bevacizumab, a humanized recombinant antibody binding to vascular endothelial growth factor (VEGF), harbored a significant activity in advanced or recurrent epithelial ovarian cancers. However, life-threatening complications including arterial thrombosis, pulmonary hemorrhage, and gastrointestinal perforation (GIP) are not negligible. A Japanese case of bowel perforation associated with bevacizumab treatment in heavily pretreated ovarian cancers is reported. The case affected with refractory ovarian cancer had no signs of bowel obstruction and bowel thickness which are now recognized as risk factors of GIP associated with bevacizumab. After obtaining a written informed consent, a combination of weekly paclitaxel and weekly bevacizumab was administered as the fourth-line therapy. After nine cycles of the regimen, the case developed GIP, although the recurrent tumor showed a stable disease. After conservative therapy for two months, the patient died. The case was severely pretreated; however, there seemed to be no risk factors for GIP. Therefore, we do recommend that special cautions are required for the bevacizumab- based chemotherapy, especially severely pretreated ovarian cancer patients.
Authors:
Masashi Takano; Yoshihiro Kikuchi; Masafumi Kato; Tomoyuki Yoshikawa; Tsunekazu Kita
Related Documents :
20624317 - Elevation of sulfatides in ovarian cancer: an integrated transcriptomic and lipidomic a...
20034397 - Mucins in ovarian cancer diagnosis and therapy.
77377 - Does pregnancy protect against ovarian cancer?
20651987 - Microcell-mediated chromosome transfer identifies epb41l3 as a functional suppressor of...
12496917 - Conservative management of clinically localized prostate cancer.
20488607 - 'containment' as an analytical framework for understanding patient delay: a qualitative...
Publication Detail:
Type:  Case Reports; English Abstract; Journal Article    
Journal Detail:
Title:  Gan to kagaku ryoho. Cancer & chemotherapy     Volume:  35     ISSN:  0385-0684     ISO Abbreviation:  Gan To Kagaku Ryoho     Publication Date:  2008 Nov 
Date Detail:
Created Date:  2008-11-17     Completed Date:  2008-12-23     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  7810034     Medline TA:  Gan To Kagaku Ryoho     Country:  Japan    
Other Details:
Languages:  jpn     Pagination:  1981-4     Citation Subset:  IM    
Affiliation:
Dept. of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Monoclonal / adverse effects*,  therapeutic use*
Antibodies, Monoclonal, Humanized
Female
Humans
Intestinal Obstruction / radiography
Intestinal Perforation / chemically induced*,  radiography
Middle Aged
Neoplasm Recurrence, Local / drug therapy*,  radiography
Ovarian Neoplasms / drug therapy*,  radiography,  surgery
Tomography, X-Ray Computed
Treatment Failure
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V/bevacizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A case of unresectable advanced thymic carcinoma in an elderly woman responding to S-1 with good QOL...
Next Document:  A case of primary unknown cancer responding to CDGP/S-1